It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time, they can do some serious damage also. Some of these companies not just tackle serious issues like cancer, but also prove to be a life-saving medicine in an investor’s portfolio. Despite the high risks involved in this sector, Celgene (CELG) has been one stable company. Despite the rough journey it had last year due to the failure of one of its key experiment drug, FDA’s refusal of reviewing its multiple sclerosis drug last month, and its disappointing long-term outlook, the company is confident to bounce back and expects profits for this year to be around three times more than they were in 2014. The growth story continues to be strong at Celgene. The company’s key product Revlimid has been one of the main growth factors, but also turns out to be the biggest problem for the company.
